UPDATE: Dougherty & Company Raises PT to $15,50 on IntegraMed America; Solid Q1

Dougherty & Company increases its price target from $12.50 to $15,50 on Buy-rated IntegraMed America

following solid results for Q1. Dougherty & Company comments, "INMD reported 1Q adjusted EPS of $0.11 vs. $0.08 (+37.5%) which exceeded our $0.10 forecast by $0.01. Revenue was $70.8 million vs. $64.3 million (+10.1%) which was in line with our forecast ($71.2 million) in what continues to be a soft consumer (and health care) economy. We have adjusted our forecast as noted above the table at the top of this note. We are optimistic about the outlook but we do not want to get the cart ahead of the horse in this situation." INMD closed at $12.87 on Monday.